Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study by Wang, Lisa et al.
Accepted Manuscript
Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of
Parkinson’s disease: analysis of a large multi-center study
L. Wang, MS, M.G. Heckman, MS, J.O. Aasly, MD, G. Annesi, PhD, M. Bozi, MD,
S.J. Chung, MD, C. Clarke, MD, D. Crosiers, MD, G. Eckstein, PhD, G. Garraux, MD,
G.M. Hadjigeorgiou, MD, N. Hattori, MD, PhD, B. Jeon, MD, Y.J. Kim, MD PhD, M.
Kubo, S. Lesage, PhD, J.J. Lin, MD, T. Lynch, MD, P. Lichtner, PhD, G.D. Mellick,
PhD, V. Mok, MD, K.E. Morrison, MD, A. Quattrone, MD, W. Satake, MD PhD, P.A.
Silburn, MD, L. Stefanis, MD, J.D. Stockton, MD, E.K. Tan, MD, T. Toda, MD PhD,
A. Brice, MD, C. Van Broeckhoven, PhD, R.J. Uitti, MD, K. Wirdefeldt, MD PhD,
Z. Wszolek, MD, G. Xiromerisiou, MD, D.M. Maraganore, MD, T. Gasser, MD, R.
Krüger, MD, M.J. Farrer, PhD, O.A. Ross, PhD, M. Sharma, PhD
PII: S0197-4580(16)30236-6
DOI: 10.1016/j.neurobiolaging.2016.09.022
Reference: NBA 9735
To appear in: Neurobiology of Aging
Received Date: 30 June 2016
Revised Date: 27 September 2016
Accepted Date: 28 September 2016
Please cite this article as: Wang, L., Heckman, M.G., Aasly, J.O., Annesi, G., Bozi, M., Chung, S.J.,
Clarke, C., Crosiers, D., Eckstein, G., Garraux, G., Hadjigeorgiou, G.M., Hattori, N., Jeon, B., Kim,
Y.J., Kubo, M., Lesage, S., Lin, J.J., Lynch, T., Lichtner, P., Mellick, G.D., Mok, V., Morrison, K.E.,
Quattrone, A., Satake, W., Silburn, P.A., Stefanis, L., Stockton, J.D., Tan, E.K., Toda, T., Brice, A., Van
Broeckhoven, C., Uitti, R.J., Wirdefeldt, K., Wszolek, Z., Xiromerisiou, G., Maraganore, D.M., Gasser, T.,
Krüger, R., Farrer, M.J., Ross, O.A., Sharma, M., on behalf of the GEOPD consortium, Evaluation of the
interaction between LRRK2 and PARK16 loci in determining risk of Parkinson’s disease: analysis of a
large multi-center study, Neurobiology of Aging (2016), doi: 10.1016/j.neurobiolaging.2016.09.022.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
 
Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson’s 
disease: analysis of a large multi-center study 
 
L. Wang MS
1
, M.G. Heckman MS
2
, J. O. Aasly MD
3
, G. Annesi PhD
4
, , M. Bozi MD
5,6
, S. J. Chung MD
 7
, 
C. Clarke MD
 8
, D. Crosiers MD
9-11
,
 
 G. Eckstein PhD
12
, G. Garraux MD
 13
, G. M. Hadjigeorgiou MD
 14
,  N. 
Hattori MD, PhD
15
, B. Jeon MD
 16
, Y. J. Kim MD PhD
 17
, M. Kubo
18
,  S. Lesage PhD
19
, J. J. Lin MD
 20
, T. 
Lynch MD
 21
, P. Lichtner PhD
 12
,  G. D. Mellick PhD
 22
, V. Mok MD
23
, 
 
K. E. Morrison MD
 24
, A. Quattrone 
MD
25 
, W. Satake MD PhD
26
, , P. A. Silburn MD
 27
, L. Stefanis MD
 6,28
, J. D. Stockton MD
 29
,
 
E. K. Tan 
MD
30,31
, T. Toda MD PhD
26
, A. Brice MD
19
, 
 
C. Van Broeckhoven PhD
9,10
, R. J. Uitti MD
 32
, K. Wirdefeldt 
MD PhD
33
, Z. Wszolek MD
32
, G. Xiromerisiou MD
14
,  D. M. Maraganore MD
34
,
  
T. Gasser MD
35
, R. 
Krüger MD
 35,,36
, M. J. Farrer PhD
37
, O. A. Ross PhD
38
,  M. Sharma
 
PhD
1 ,35
 on behalf of the GEOPD 
consortium.  
  
1.  Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, 
University of Tubingen, Germany 
2.  Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida 
3.  Department of Neurology, St Olavs hospital and NTNU Trondheim, Norway 
4.  Institute of Molecular Bioimaging and Physiology, National Research Council, Section of Catanzaro 
Italy  
5.  Psychiatry Athens Hospital, Neurology Department, Athens 
6.  2nd Neurology Clinic, University of Athens, Attikon Hospital, Athens 
7.  Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 
Korea 
8. School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of 
Birmingham, UK and City Hospital, Birmingham. 
9. Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, 
Belgium 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
10. Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.  
11. Department of Neurology, University Hospital Antwerp, Antwerp, Belgium.  
12. Helmholtz Zentrum München, German Research Centre for Environmental Health (Gmbh), 
IngolstaedterLandstr. 1, 85764 Neuherberg, Germany  
13. Cyclotron Research Centre, Department of Neurology, University of Liège, Sart Tilman B30, 4000 
Liège- Belgium. 
14. Department of Neurology, Faculty of Medicine, University of Thessaly and Institute of Biomedical 
Research and Technology, CERETETH, Larissa 
15. Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan 
16. Institute Department of Neurology, Seoul National University Hospital 
17. ILSONG Institute of Life Science, Hallym University, Hallym Institute of Translational Genomics & 
Bioinformatics, Department of Neurology, Hallym University Sacred Heart Hospital, Korea   
18. Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, 
Yokohama, Japan.  
19.  INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, 
Institut du Cerveau et de la Moelle épinière, ICM, Paris, France 
20. Department of Neurology, Chushang Show-Chwan Hospital, Nantou and Chung-Shan Medical 
University Hospital, Taichung, Taiwan 
21. The Dublin Neurological Institute at the Mater Misericordiae University Hospital, and Conway 
Institute, University College Dublin, Ireland 
22. Eskitis Institute for Cell and Molecular Therapies, Griffith University, Australia 
23. Clinical Neurology Research Centre, Department of Medicine & Therapeutics, The Chinese 
University of Hong Kong, 10/F, Clinical Sciences Building,  Prince of Wales Hospital, Shatin, New 
Territories, Hong Kong 
24. Faculty of Medicine, University of Southampton, Southampton, UK. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
25. Institute of Neurology, Department of Medical Sciences, University Magna Graecia, Catanzaro, 
Italy and Institute of Molecular Bioimaging and Physiology, National Research Council, Section of 
Catanzaro Italy 
26. Division of Neurology/Molecular Brain Science, Kobe University Graduate School of Medicine 
27. University of Queensland Centre for Clinical Research, Herston, Australia. 
28. Divisions of Basic Neurosciences & Cell Biology, Biomedical Research Foundation of Academy 
of Athens, Athens 11527, Greece 
29. Neurosciences Department, Queen Elizabeth Hospital Birmingham, University Hospitals 
Birmingham NHS Foundation Trust. 
30. Department of Neurology, Singapore General Hospital, National Neuroscience Institute, 
Singapore.  
31. Duke-NUS Graduate Medical School 
32. Department of Neuroscience, Mayo Clinic Jacksonville, USA. 
33. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden. 
34. Department of Neurology, NorthShore University HealthSystem, Evanston, IL, USA 
35. Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Science Research, 
University of Tubingen, Germany 
36. Clinical and Experimental Neuroscience, Luxembourg Centre for Systems Biomedicine, University 
of Luxembourg, and Centre Hospitalier de Luxembourg (CHL), Luxembourg. 
37. Djavad Mowafhagian Centre for Brain, University of British Columbia, Vancouver, British 
Columbia, Canada V6T 2B5 
38. Department of Neurology, Mayo Clinic Jacksonville, USA 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
Abstract: A recent study has shown that an interaction between variants at the LRRK2 and PARK16 
loci influences risk of development of PD (MacLeod D. et al, 2013). Our study examines the proposed 
interaction between LRRK2 and PARK16 variants in modifying PD risk using a large multi-center series 
of PD patients (5769) and controls (4988) from sites participating in the Genetic Epidemiology of 
Parkinson’s Disease (GEoPD) consortium. Our data does not support a strong direct interaction 
between LRRK2 and PARK16 variants; however given the role of retromer and lysosomal pathways in 
PD, further studies are warranted. 
1. Introduction:  Genetic discoveries made over the years either by using linkage, array and/or 
exome based approaches have helped in advancing our knowledge of the genetic underpinnings of 
PD (Trinh J., Farrer M., 2013; Lesage S., Brice. A., 2013; International Parkinson Disease Genomics 
Consortium et al., 2011). As we discover new loci relevant to idiopathic PD pathogenesis, it has 
become imperative to also understand the gene-gene interaction effect in modulating PD risk in 
population (see supplementary information) (Elbaz A., et al., 2011). Although the results of most 
gene-gene interactions studies in PD to date have pointed toward independent effects for PD 
susceptibility variants, an exception to this has been an assessment of functional-genetic interaction 
between the LRRK2 and PARK16 loci in which overexpression of RAB7L1, a candidate gene for 
PARK16 locus, reversed the effects of the LRRK2 mutation and rescued the phenotypes (MacLeod D., 
et al., 2013). Therefore, this study aims to evaluate the interaction between several different LRRK2 
and PARK16 variants in determining PD risk using a Caucasian series with more than 10,000 subjects 
from 14 different centers, and an Asian series with more than 5,000 subjects from five different 
centers.  
2. Methods:  The GEoPD consortium includes investigators from 59 sites, across 30 countries and 6 
continents, as of 2016. A total of 19 sites representing 17 countries and four continents agreed to 
contribute DNA samples and clinical data for the current study. In total, 15,976 subjects were 
included in this study, divided into a Caucasian series (5769 PD patients, 4988 controls) and an Asian 
series (1946 PD patients, 3273 controls). We selected five SNPs for the PARK16 locus (rs823139 
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[RAB7L1], rs708725 [RAB7L1], rs823156 [SLC41A1], rs11240572 [PM20D1], and rs708723 [RAB7L1]) 
because previously published studies suggested associations with PD risk and the respective sites 
also provided coverage of the PARK16 locus. We selected two SNPs from the LRRK2 gene (rs1491942, 
rs7133914) due to previously demonstrated associations with PD and minor allele frequencies high 
enough to allow for reasonable interaction analysis. Analysis was performed separately for the 
Caucasian series, the Asian series, and the combined series. We evaluated single variant associations 
using fixed effects logistic regression models adjusted for GEoPD site. Pair-wise multiplicative 
interactions between LRRK2 and PARK16 variants were also examined using fixed effects logistic 
regression models. In addition to including terms for the given two individual variants and their 
interaction, these models were adjusted for the individual GEoPD site. Odds ratios (ORs) and 95% 
confidence intervals (CIs) were estimated. Subjects were coded as either 0 (absence of the minor 
allele) or 1 (presence of the minor allele) for each variant. Variants with a MAF of 10% or greater in 
both the Asian and Caucasian series were examined under an additive model, with the subject coded 
as (0,1,2), depending on the number of copies of the minor allele. In order to account for the 10 tests 
of LRRK2-PARK16 interaction that were performed in each series (Caucasian, Asian, or combined), we 
utilized a Bonferroni correction for multiple testing separately in each series, after which 2-sided p-
values of 0.005 or lower were considered as statistically significant. All statistical analyses were 
performed using R Statistical Software. The local Ethics Committee at each GEoPD site approved the 
study. All participants signed an informed consent. 
3. Results: Of the ten interactions that were examined between the PARK16 and LRRK2 variants, 
non-significant  evidence of gene-gene interaction was observed between LRRK2 rs1491942 and 
PARK16 rs11240572 in the combined series (Interaction OR: 0.97, 95% CI: 0.74 – 1.01, P=0.07, Table 
1). PARK16 rs11240572 appeared to have no effect on PD risk for individuals with the common GG 
genotype for LRRK2 rs1491942, but a slight protective effect for those with GC and CC LRRK2 
rs1491942 genotypes (see supplementary information). Investigating this further in the stratified 
data (Supplementary Table 6), we observed for non-carriers of PARK16 rs11240572, LRRK2 
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rs1491942 a statistically significant higher risk of PD development in the Caucasian and combined 
series (OR 1.17 and 1.15, P value <0.001). However, after correcting for multiple testing, it no longer 
approached statistical significance under the interaction model. There were no other noteworthy 
interactions between LRRK2 rs1491942 and PARK16 variants in any series (all interaction P≥0.25, 
Supplementary Tables 3-5), or between LRRK2 rs7133914 and PARK16 variants in the Caucasian 
series (all interaction P≥0.096, Supplementary Table 7). Interaction ORs ranged between 0.85 and 
1.20, which supports the lack of a biologically meaningful interaction by lack of a notable deviation 
from an OR of 1. Between-site heterogeneity in interaction effects was generally relatively low 
(ranges between 0% to 35% with most around 0%), lending consistency to the lack of interaction. 
Models adjusted for age and gender using the subset of subjects with complete information and 
random effects models also produced similar results in gene-gene interaction analyses. 
4.  Discussion: The identification of genetic mutations in genes linked to familial forms of PD (e.g. 
LRRK2, VPS35, DNAJC13) and genetic variability within the PARK16 locus in GWAS strongly implicates 
the role of retromer and lysosomal pathway in PD pathogenesis (Heckman M.G., et al., 2014; Soto-
Ortolaza A.I., et al., 2013).  Therefore, to understand the impact of interaction in world-wide 
populations, we performed a large multi-center study to assess the genetic evidence of interaction 
between LRRK2 and PARK16 locus. The results of our study do not provide evidence of a genetic 
interaction between PARK16 and LRRK2 variants with regard to risk of PD. Of note, the directionality 
of effect estimates, albeit with a much weaker effect size observed in the present study, involving 
the specific LRRK2 rs1491942/PARK16 rs11240572 interaction are in agreement  with previously 
published findings. Genetic interaction studies are limited by sample size and power because the 
variable of focus in an interaction study is the presence of the genotype of interest for both variants, 
and this occurs much less frequently than the individual variant genotypes.  
Therefore even with our large sample size, power is still limited to detect moderate to small gene-
gene interaction effects. While there was some degree of concordance between our interaction 
findings and those that were previously reported, our results were much weaker than the strong 
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LRRK2-PARK16 interaction that was previously reported (Beilina A., et al., 2014; MacLeod D., et al., 
2013). Even with the large GEoPD sample size, which we have accrued to perform the current study, 
we are likely underpowered to detect weaker interaction effects. Additionally, lack of genetic 
interaction does not exclude the presence of cellular or functional interaction. However, such genetic 
studies will be critical if we are to understand the role of gene-gene interaction in disease 
susceptibility. 
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